NCT06576466 Effect of Supplementation With Creatine on the Recovery of Ischemic Stroke
| NCT ID | NCT06576466 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundació d'investigació Sanitària de les Illes Balears |
| Condition | Stroke, Ischemic |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2024-09-27 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 92 participants in total. It began in 2024-09-27 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stroke is a leading cause of disability and the second leading cause of death worldwide. Most strokes are ischemic, caused by acute arterial occlusion. Post-stroke treatment focuses on secondary prevention and rehabilitation, but few treatments address functional recovery. Creatine, a supplement known for improving physical performance, may aid in the recovery of stroke patients, reducing sarcopenia and improving strength among other effects. This pilot study will investigate the effectiveness of creatine supplementation in enhancing physical and functional recovery in ischemic stroke patients. The study will involve a randomized, double-blind clinical trial comparing creatine monohydrate to a placebo.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 80 years * Recent diagnosis of ischemic stroke (from 24 hours to 5 days) . * Neurological deficit due to the stroke that affects mobility (paresis and/or ataxia) and requires motor rehabilitation. * Ability to understand and sign the informed consent form, or failing that, have sufficient support to carry out the correct follow-up of the study. Exclusion Criteria: * Moderate-severe disability prior to stroke, defined by an mRS\>2. * Unstable or severe clinical situation that prevents active rehabilitation. * Neurological deficit due to stroke that prevents walking without help from another person. The use of support with a cane, crutch or walker is permitted. * Moderate or severe dysphagia that makes therapeutic adherence difficult. * Use of creatine supplements in the last 3 months, or use of anabolic products in the last 3 months. * Severe kidney disease (GFR \<30ml/min/1.73 m2). * Musculoskeletal pathology that prevents assessment of muscle strength. For example: fractures, severe osteoarthritis, ligament tears or tendinopathies. * History of allergic reactions to creatine. * Pregnancy or breastfeeding. * Simultaneous participation in another clinical trial.
Contact & Investigator
Raquel Delgado Mederos, PhD
PRINCIPAL INVESTIGATOR
Fundació d'investigació Sanitària de les Illes Balears
Frequently Asked Questions
Who can join the NCT06576466 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke, Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06576466 currently recruiting?
Yes, NCT06576466 is actively recruiting participants. Contact the research team at raquel.delgado@ssib.es for enrollment information.
Where is the NCT06576466 trial being conducted?
This trial is being conducted at Palma de Mallorca, Spain.
Who is sponsoring the NCT06576466 clinical trial?
NCT06576466 is sponsored by Fundació d'investigació Sanitària de les Illes Balears. The principal investigator is Raquel Delgado Mederos, PhD at Fundació d'investigació Sanitària de les Illes Balears. The trial plans to enroll 92 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.